Overview / Abstract: |
Chronic lymphocytic (CLL) and chronic myelogenous (CML) leukemia are commonly diagnosed and treated by community oncologists. Whereas, in the past, these hematologic malignancies were considered incurable, new therapies have challenged that notion. Educational Objectives -Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care -Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with chronic leukemia -Discuss current recommendations for diagnostic testing for chronic leukemia to facilitate treatment selection -Assess the safety and efficacy of approved and emerging therapies for primary and subsequent management of chronic leukemia with attention to cost/benefit and toxicity considerations -Employ resources to increase patient access and engagement |
Expiration |
Jan 24, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
AACME - 1.00 AMA PRA Category 1 Credit; ACPE - 1.00 hours (0.1 CEUs); ANCC - 1.1 contact hours; APRN - 0.3 contact hours pharmacology credit |
Accreditation |
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology |
Presenters / Authors / Faculty |
Saar Gill, MD, PhD |
Activity Specialities / Related Topics |
Pharmacology, Oncology / Cancer / Radiation Therapy, Nutrition / Dietary, Immunology / Immunosuppression, Hematology, Genetics, Administration / Management |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. |
Keywords / Search Terms |
Rockpointe, chronic lymphocytic leukemia, CLL, chronic myelogenous leukemia, CML,Tyrosine kinase inhibitors, TKIs, immunotherapy, CAR-T cells, oncology, hematology, tumor types, CAR-T therapy,PCME, Free CE CME |